Biotech, cancer, Melanoma

Synta Melanoma Data Coming in May

Luke Timmerman 2/2/09

Synta, the Lexington, MA-based developer of cancer drugs, said today it has completed enrolling 630 patients in a clinical trial of its lead product candidate for melanoma that has spread through the body. The company (NASDAQ: SNTA) has a goal of releasing results from the study in May. We profiled Synta’s efforts to develop this drug, elesclomol, last month.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.